A fixed dose combination of ibuprofen and famotidine

Bibliography

• Verhaak P, Kerssens J, Dekker J, et al. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998;77(3):231-9
   PubMed Web of Science ®Google Scholar
• James F, Large R, Bushnell J, Wells J. Epidemiology of pain in New Zealand. Pain 1991;44(3):279-83
   PubMed Web of Science ®Google Scholar
• Latham J, Davis B. The socioeconomic impact of chronic pain. Disabil Rehabil 1994;16(1):39-44
   PubMedGoogle Scholar
• Luo X, Pietrobon R, Sun S, et al. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine 2004;29(1):79-86
   PubMed Web of Science ®Google Scholar
• Vane J, Flower R, Botting R. History of aspirin and its mechanism of action. Stroke 1990;21(Suppl 12):IV12-23
   PubMedGoogle Scholar
• Roelofs P, Deyo R, Koes B, et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev 2008(1):CD000396
   PubMedGoogle Scholar
• Holdgate A, Pollock T. Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev 2005(2):CD004137
   PubMedGoogle Scholar
• McNicol E, Strassels S, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005(1):CD005180
   Google Scholar
• Suthisisang C, Poolsup N, Kittikulsuth W, et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007;41(11):1782-91
   PubMed Web of Science ®Google Scholar
• Raofi S, Schappert S. Medication therapy in ambulatory medical care: United States, 2003-04. Vital Health Stat 13 2006;163:1-40
   PubMedGoogle Scholar
• Larkai E, Smith J, Lidsky M, Graham D. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82(11):1153-8
   PubMed Web of Science ®Google Scholar
• Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999;56:18-24
   PubMedGoogle Scholar
• Hoftiezer J, O'laughlin J, Ivey K. Effects of 24 hours of aspirin, bufferin, paracetamol and placebo on normal human gastroduodenal mucosa. Gut 1982;23(8):692-7
   PubMed Web of Science ®Google Scholar
• Singh G, Ramey D, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156(14):1530-6
   PubMed Web of Science ®Google Scholar
• Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105(1B):31S-8S
   PubMedGoogle Scholar
• Chen Y, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12(11):1-278, iii
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-44
   PubMed Web of Science ®Google Scholar
• Malagelada J, Rodríguez de la Serna, Dammann H, et al. Sucralfate therapy in NSAID bleeding gastropathy. Clin Gastroenterol Hepatol 2003;1(1):51-6
   PubMed Web of Science ®Google Scholar
• Miglioli M, Bianchi Porro G, Vaira D, et al. Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients. AmJ Gastroenterol 1996;91(11):2367-71
   PubMed Web of Science ®Google Scholar
• Robinson M, Griffin JJ, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989;34(3):424-8
   PubMed Web of Science ®Google Scholar
• Ehsanullah R, Page M, Tildesley G, Wood J. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297(6655):1017-21
   PubMed Web of Science ®Google Scholar
• Taha A, Hudson N, Hawkey C, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334(22):1435-9
   PubMed Web of Science ®Google Scholar
• Yeomans N, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338(11):719-26
   PubMed Web of Science ®Google Scholar
• Hawkey C, Karrasch J, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med;338(11):727-34
   PubMed Web of Science ®Google Scholar
• Agrawal N, Roth S, Graham D, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 1991;115(3):195-200
   PubMed Web of Science ®Google Scholar
• Bianchi Porro G, Lazzaroni M, Petrillo M. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients. Am J Gastroenterol 1997;92(4):663-7
   PubMed Web of Science ®Google Scholar
• Raskin J, White R, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol 1996;91(2):223-7
   PubMed Web of Science ®Google Scholar
• Raskin J, White R, Jackson J, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123(5):344-50
   PubMed Web of Science ®Google Scholar
• Patel B, Leslie R, Thiebaud P, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4(3):673-81
   PubMedGoogle Scholar
• Vanderpoel D, Hussein M, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004;26(12):2066-75
   PubMed Web of Science ®Google Scholar
• Melikian C, White T, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24(3):460-7
   PubMed Web of Science ®Google Scholar
• Adams S, Cliffe E, Lessel B, Nicholson J. Some biological properties of 2-(4-isoburylphenyl)-propionic acid. J Pharm Sci 1967;56(12):1686
   PubMed Web of Science ®Google Scholar
• Vane J, Botting R. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44(1):1-10
   PubMed Web of Science ®Google Scholar
• Sharma S, Prasad A, Anand K. Nonsteroidal anti-inflammatory drugs in the management of pain and inflammation: a basis for drug selection. Am J Ther 1999;6(1):3-11
   PubMedGoogle Scholar
• Evans A. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1992;42(3):237-56
   PubMed Web of Science ®Google Scholar
• Baillie T, Adams W, Kaiser D, et al. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans. J Pharmacol Exp Ther 1989;249(2):517-23
   PubMed Web of Science ®Google Scholar
• Evans A, Nation R, Sansom L, et al. The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. Biopharm Drug Dispos 1990;11(6):507-18
   Google Scholar
• Rudy A, Bradley J, Ryan S, et al. Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients. Ther Drug Monit 1992;14(6):464-70
   PubMed Web of Science ®Google Scholar
• Lee E, Williams K, Day R, et al. Stereoselective disposition of ibuprofen enantiomers in man. 1985. Br J Clin Pharmacol 2004;58(7):S759-64; discussion S65-7
   PubMed Web of Science ®Google Scholar
• Cook D, Reeve B, Guyatt G, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996;275(4):308-14
   PubMed Web of Science ®Google Scholar
• Howard J, Chremos A, Collen M, et al. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 1985;88(4):1026-33
   PubMed Web of Science ®Google Scholar
• Cheng H, Rogers J, Demetriades J, et al. Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. Pharm Res 1994;11(6):824-30
   PubMed Web of Science ®Google Scholar
• Davies N. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998;34(2):101-54
   PubMed Web of Science ®Google Scholar
• Mills R, Adams S, Cliffe E, et al. The metabolism of ibuprofen. Xenobiotica 1973;3(9):589-98
   PubMed Web of Science ®Google Scholar
• Adams S, Bough R, Cliffe E, et al. Some aspects of the pharmacology, metabolism, and toxicology of ibuprofen. I. Pharmacology and metabolism. Rheumatol Phys Med 1970;10(Suppl 10):9-26
   PubMedGoogle Scholar
• Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 1991;21(3):178-94
   PubMed Web of Science ®Google Scholar
• De Gara C, Burget D, Chremos A, et al. The effects of intravenous famotidine on pentagastrin-stimulated gastric secretion in man. Aliment Pharmacol Ther 1987;1(2):125-32
   PubMedGoogle Scholar
• Ryan J, Vargas R, McMahon F, Chremos A. Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion. Am J Med 1986;81(4B):60-4
   PubMed Web of Science ®Google Scholar
• Jenkinson M, Fitzpatrick R, Streete P, Volans G. The relationship between plasma ibuprofen concentrations and toxicity in acute ibuprofen overdose. Hum Toxicol 1988;7(4):319-24
   PubMedGoogle Scholar
• Tidmarsh G, Rodriguez S. A novel combination of ibuprofen (Ibu) and famotidine (FAM), provides pharmacokinetics comparable to that of commercially available Ibu and Fam in a patient-friendly dosing form: evaluation in healthy and renally-impaired subjects. Gastroenterology 2009;136(5):A612
   Google Scholar
• Daneshmend T, Prichard P, Bhaskar N, et al. Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by famotidine. Gastroenterology 1989;97(4):944-9
   PubMed Web of Science ®Google Scholar
• Aabakken L, Bjørnbeth B, Weberg R, et al. NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum? Aliment Pharmacol Ther 1990;4(3):295-303
   PubMed Web of Science ®Google Scholar
• Lanza F, Chan F, Quigley E. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104(3):728-38
   PubMed Web of Science ®Google Scholar
• Yamao J, Kikuchi E, Matsumoto M, et al. Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE–famotidine or rebamipide in comparison by endoscopy). J Gastroenterol 2006;41(12):1178-85
   PubMed Web of Science ®Google Scholar
• Miyake K, Ueki N, Suzuki K, et al. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. Aliment Pharmacol Ther 2005;21(Suppl 2):67-72
   PubMed Web of Science ®Google Scholar
• Laine L, Schiff M, Genovese M. Does high-dose famotidine reduce gastric and duodenal ulcers in NSAID users? Two double-blind six-month trials of single-tablet combination ibuprofen-famotidine vs. ibuprofen alone (Reduce-1 and 2). Gastroenterology 2009;136(5):A69
   Google Scholar